From Our Perspective
Posted on October 29, 2020
By 340B Matters
Senator Lamar Alexander (R-Tenn.) and Rep. Greg Walden (R-Ore.) have asked stakeholders in the 340B Drug Discount Program to submit ideas on how it can be improved. It’s a request that both pharmaceutical manufacturers and safety-net healthcare providers should take seriously.
With a few updates, the...
Posted on October 13, 2020
By 340B Matters
The drug industry and its surrogates have contended for years that the 340B Drug Discount Program somehow raises drug prices overall.
It has argued that discounts provided under 340B to safety-net hospitals and clinics are offset by manufacturers when selling those same medicines at...
Posted on October 08, 2020
By 340B Matters
The drug industry is spoiling for a legal fight over the 340B Drug Discount Program. Safety-net hospitals and clinics should give them one by suing over clear breaches of federal law.
By turns peremptory and obnoxious, Eli Lilly, AztraZeneca, Merck and Sanofi have unilaterally...
Posted on September 28, 2020
By 340B Matters
In response to Big Pharma’s recent unprecedented attacks on the 340B Drug Discount Program, Congress and the Department of Health and Human Services have put the manufacturers on notice that their actions may be formally rebuked by the federal government.
HHS General Counsel Robert...
Posted on September 14, 2020
By 340B Matters
Safety-net healthcare providers and first responders on the front lines of a global pandemic are facing an illegal campaign from drug companies to raise drug prices. These heroes have asked Health and Human Services Secretary Alex Azar to intervene.
His silence is deafening.
Azar is...
Posted on August 31, 2020
By 340B Matters
Setting rules without enforcement?
That’s ridiculous.
But that’s just what’s happening with the 340B Drug Discount Program as the federal agency that oversees it has decided to walk off the job. The Health Resources and Services Agency has been the arbiter of the 340B program for almost 30 years....
Posted on August 20, 2020
By 340B Matters
Mega drugmaker AstraZeneca has decided now is the ideal time to overcharge safety-net healthcare providers valiantly fighting the global pandemic.
The company announced, starting October 1, it will stop offering lower pricing to America’s safety-net providers participating in the 340B Drug Discount Program if...
Posted on August 07, 2020
By 340B Matters
Just as safety-net healthcare providers face historic budget shortfalls due to the pandemic, Big Pharma has launched an attack on the 340B Drug Discount Program while the federal agency overseeing it has suspiciously turned away.
Eli Lilly, Merck and Sanofi have unilaterally undermined the...
By 340B Matters
Big Pharma has spent years and millions of dollars in an unsuccessful campaign to destroy a program that strengthens our nation’s public health system at no cost to taxpayers: the 340B Drug Discount Program. Because of strong bi-partisan support for 340B in Congress,...
By 340B Matters
During the coronavirus era, the pharmaceutical industry is hoping to receive an undeserved pass on high drug prices. But while many people now look to Big Pharma for a vaccine salvation, old habits haven’t changed.
Pharmaceutical manufacturers are attempting to cast themselves as angels...